Abstract:
Objective To evaluate the outcome and prognosis of lung cancer patients with bony metastases wno underwent multimodal treatment.
Methods The data of 258 lung oancer patients with bony metastases were analyzed retrospectively. The survival rates were calculated using the Kaplan - Meier method. The log-rank method was used for univariate analysis, and the Cox regression model was used for multivariate analysis. Clinical data of 258 lung cancer patients with bony metastases admitted to the Shanghai Hospital of Pulmonary Diseases from February 2006 to February 2008 were retrospectively analyzed.
Results The one and two-year survival rates of the patients were 52.6% and 26.5%, respectively. The median survival time was 12.6 months for patients with bony metastases from lung cancer. Univariate analysis showed that the PS score, number of osseous metastases, possibility of chemotherapy after metastasis, as well as serum AKP and CA242 levels were prognostic factors (P < 0.001). Multivariate analysis indicated that the clinical stage, AKP level, chemotherapy after metastasis, and PS score were independent prognostic factors.
Conclusion The bony metastasis of lung adenocarcinoma ranks first in the incidence of tumor metastases. The predilection sites of bony metastases are in the order of spine, pelvis, and ribs. The clinical stage at first visit, serum AKP, number of osseous metastasis, and PS score at first visit greatly influence the prognosis of patients with bony metastasis from lung cancer.